BIAF closes ~$4.0M private placement of 8.46M pre-funded warrants with 2 detachable warrants/unit
AI Summary
BioAffinity (BIAF / BIAFW) closed a private placement priced at-the-market raising approximately $4.0M gross by selling pre-funded warrants to purchase 8,462,027 shares; each pre-funded warrant was sold with two detachable common warrants at a combined effective price of $0.4657. The pre-funded warrants carry a $0.007 exercise price (allowing issuance of common stock upon exercise), the detachable common warrants have a $0.4727 strike, expire in five years and will be exercisable only following stockholder approval; WallachBeth Capital was sole placement agent. Timing: Warrant exercises are already completed, so dilution is already in effect.
Positives
- Sale structured as pre-funded warrants (8,462,027) which delay actual share issuance until exercised
Negatives
- Potential dilution if 8.46M pre-funded warrants are exercised into common shares
- Two detachable common warrants per pre-funded warrant (~16.9M warrants) add additional potential dilution if exercised
- Common warrants not exercisable until stockholder approval, creating uncertainty on timing of further dilution
Filing Context
Filing and Dilution Context
Earliest dilution
Earliest dilution: already triggered
Dilution status
live_now
Dilution timing
Dilution status: Immediate
Trigger type
already_triggered